A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Seagen Inc.
Merck Sharp & Dohme LLC
Toray Industries, Inc
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc